Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
On February 20, 2026, the U.S. FDA approved the combination of Venclexta (venetoclax) and acalabrutinib for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This landmark decision establishes the first and only all-oral, fixed-duration (time-limited) regimen for previously untreated patients, offering a significant alternative to continuous therapy or chemoimmunotherapy
GSK plc (LSE/NYSE: GSK) today announced positive results from its pivotal Phase III clinical trial program for bepirovirsen. This investigational treatment could redefine the standard [Read More…]
If 2024 was the year of “hype” for AI and GLP-1s, 2025 became the year of clinical delivery. We moved beyond the theoretical promise of [Read More…]
Novo Nordisk has officially submitted a New Drug Application to the FDA for CagriSema, a first-of-its-class once-weekly injection for chronic weight management. Combining semaglutide with a novel amylin analogue, clinical data from the REDEFINE program shows the treatment can achieve over 20% weight loss in adults with obesity.
Biomoneta is the first Indian health-tech firm to receive US-FDA Class II clearance for its Avata Rx Medical Air Cleaner, which uses patented ZeBox technology for >99.9999 pathogen elimination.
Dr. Jogin Desai presents Eyecyte-RPE™ data at Innoxbio CGT 2025 in China, showing a 14.8-letter average gain in visual acuity and a strong safety profile.
Dr. James D. Watson, the Nobel laureate who fundamentally changed biology by co-discovering the DNA double helix, has died at 97. While his 1953 breakthrough ushered in the age of modern genetics
Eli Lilly has announced a $3 billion investment to build a new, state-of-the-art manufacturing facility in Katwijk, Netherlands. Located in the Leiden Bio Science Park, the advanced plant will significantly expand the company’s capacity for its growing portfolio of oral medicines, including the oral GLP-1 drug orforglipron.
Eli Lilly and Company (NYSE: LLY) announced on Friday that it has reached a final agreement to purchase clinical-stage gene therapy startup Adverum Biotechnologies, Inc. [Read More…]
